Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treg Infusion for aGVHD Prevention After UCB Transplant
NCT02991898Phase 2Terminated
- Sponsor
- Masonic Cancer Center
- Start
- Feb 2017
- Primary completion
- Jun 2019
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of umbilical cord blood regulatory T cells in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Masonic Cancer Center. Started Feb 2017; status: terminated.
02
Drugs
umbilical cord blood regulatory T cells
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT02991898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02991898.